Searched for: subject:"atherosclerosis"
(1 - 20 of 133)

Pages

document
van den Hoek, A.M. (author), de Jong, J.C.B.C. (author), Worms, N. (author), van Nieuwkoop, A. (author), Voskuilen, M. (author), Menke, A.L. (author), Lek, S. (author), Caspers, M.P.M. (author), Verschuren, L. (author), Kleemann, R. (author)
Background. Non-alcoholic steatohepatitis (NASH) has become one of the most common liver diseases and is still without approved pharmacotherapy. Lifestyle interventions using exercise and diet change remain the current treatment of choice and even a small weight loss (5–7%) can already have a beneficial effect on NASH. However, the underlying...
article 2021
document
van Keulen, D. (author), van Koeverden, I.D. (author), Boltjes, A. (author), Princen, H.M.G. (author), van Gool, A.J. (author), Asselbergs, F.W. (author), Tempel, D. (author), Pasterkamp, G. (author), van der Laan, S.W. (author)
Background and Aims: Oncostatin M (OSM) signaling is implicated in atherosclerosis, however the mechanism remains unclear. We investigated the impact of common genetic variants in OSM and its receptors, OSMR and LIFR, on overall plaque vulnerability, plaque phenotype, intraplaque OSMR and LIFR expression, coronary artery calcification burden and...
article 2021
document
Pouwer, M.G. (author), Pieterman, E.J. (author), Worms, N. (author), Keijzer, N. (author), Jukema, J.W. (author), Gromada, J. (author), Gusarova, V. (author), Princen, H.M.G. (author)
Atherosclerosis-related cardiovascular disease causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocumab or evinacumab-monoclonal...
article 2020
document
Pouwer, M.G. (author)
The thesis discussed several strategies that may contribute to further CVD risk reduction in the future. We described two novel lipid-lowering strategies, we unraveled (part of) the etiology of the cardiovascular safety issues of TKIs that are used for the treatment of CML, and we investigated the dose effects of PFOA on lipoprotein metabolism....
doctoral thesis 2020
document
Stokman, G. (author), van den Hoek, A.M. (author), Denker Thorbekk, D. (author), Pieterman, E.J. (author), Skovgård Veidal, S. (author), Basta, B. (author), Iruarrizaga-Lejarreta, M. (author), van der Hoorn, J.W. (author), Verschuren, L. (author), Berbée, J.F.P. (author), Rensen, P.C.N. (author), Skjæret, T. (author), Alonso, C. (author), Feigh, M. (author), Kastelein, J.J.P. (author), Friedman, S.L. (author), Princen, H.M.G. (author), Fraser, D.A. (author)
article 2020
document
van den Hoek, A.M. (author), Verschuren, L. (author), Worms, N. (author), van Nieuwkoop, A. (author), de Ruiter, C. (author), Attema, J. (author), Menke, A.L. (author), Caspers, M.P.M. (author), Radhakrishnan, S. (author), Salic, K. (author), Kleemann, R. (author)
Non-alcoholic steatohepatitis (NASH) is a fast-growing liver disorder that is associated with an increased incidence of cardiovascular disease and type 2 diabetes. Animal models adequately mimicking this condition are scarce. We herein investigate whether Ldlr−/−. Leiden mice on different high-fat diets represent a suitable NASH model. Ldlr−/−....
article 2020
document
Hardtner, C. (author), Kornemann, J. (author), Krebs, K. (author), Ehlert, C.A. (author), Jander, A. (author), Zou, J. (author), Christopher, (author), Starz, C. (author), Rauterberg, S. (author), Sharipova, D. (author), Dufner, B. (author), Hoppe, N. (author), Dederichs, T.S. (author), Willecke, F. (author), Stachon, p. (author), Heidt, T. (author), Wolf, D. (author), zur Muhlen, C.von (author), Madl, J. (author), Kohl, P. (author), Kaeser, R. (author), Boettler, T. (author), Pieterman, E.J. (author), Princen, H.M.G. (author), Ho-Tin-Noe, B. (author), Swirski, F.K. (author), Robbins, C.S. (author), Bode, C. (author), Zirlik, A. (author), Hilgendorf, I. (author)
speculative.
article 2020
document
van Broekhoven, A. (author), Krijnen, P.A.J. (author), Fuijkschot, W.W. (author), Morrison, M.C. (author), Zethof, I.P.A. (author), van Wieringen, W.N. (author), Smulders, Y.M. (author), Niessen, H.W.M. (author), Vonk, A.B.A. (author)
Background Recently, it was shown that 12 weeks of lipopolysacharide (LPS) administration to non‐atherosclerotic mice induced thickening of the aortic heart valve (AV). Whether such effects may also occur even earlier is unknown. As most patients with AV stenosis also have atherosclerosis, we studied the short‐term effect of LPS on the AVs in an...
article 2019
document
Pouwer, M.G. (author), Heinonen, S.E. (author), Behrendt, M. (author), Andréasson, A.M. (author), Koppen A. van, (author), Menke, A.L. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Jukema, J.W. (author), Leighton, B. (author), Jonsson-Rylander, A.M. (author), Princen, H.M.G. (author)
Background. There is a lack of predictive preclinical animal models combining atherosclerosis and type 2 diabetes. APOE*3-Leiden (E3L) mice are a well-established model for diet-induced hyperlipidemia and atherosclerosis, and glucokinase+/− (GK+/−) mice are a translatable disease model for glucose control in type 2 diabetes. The respective mice...
article 2019
document
Yakala, G.K. (author), Cabrera-Fuentes, H.A. (author), Crespo-Avilan, G.E. (author), Rattanasopa, C. (author), Burlacu, A. (author), George, B.L. (author), Anand, K. (author), Mayan, D.C. (author), Corliano, M. (author), Hernandez-Resendiz, S. (author), Wu, Z. (author), Schwerk, A.M.K. (author), Tan, A.L.J. (author), Trigueros-Motos, L. (author), Chevre, R. (author), Chua, T. (author), Kleemann, R. (author), Liehn, E.A. (author), Hausenloy, D.J. (author), Ghosh, S. (author), Singaraja, R.R. (author)
Objective- Atherosclerotic coronary artery disease is the leading cause of death worldwide, and current treatment options are insufficient. Using systems-level network cluster analyses on a large coronary artery disease case-control cohort, we previously identified PCSK3 (proprotein convertase subtilisin/kexin family member 3; FURIN) as a member...
article 2019
document
Schuster, S. (author), Rubil, S. (author), Endres, M. (author), Princen, H.M.G. (author), Boeckel, J.N. (author), Winter, K. (author), Werner, C. (author), Laufs, U. (author)
LDL-cholesterol (LDL-C) is a causal pathogenic factor in atherosclerosis. Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing antibodies are novel potent LDL-lowering drugs which reduce cardiovascular events. To characterize their effect on atherogenesis, APOE*3Leiden.CETP mice were fed a high cholesterol/high fat...
article 2019
document
van Keulen, D. (author), Pouwer, M.G. (author), Emilsson, V. (author), Matic LP, (author), Pieterman, E.J. (author), Hedin, U. (author), Gudnason, V. (author), Jennings, L.L. (author), Holmstrøm, K. (author), Nielsen, B.S. (author), Pasterkamp, G. (author), Lindeman, J.H.N. (author), van Gool, A.J. (author), Sollewijn Gelpke, M.D. (author), Princen, H.M.G. (author), Tempel, D. (author)
OBJECTIVE: Previous studies indicate a role for Oncostatin M (OSM) in atherosclerosis and other chronic inflammatory diseases for which inhibitory antibodies are in development. However, to date no intervention studies with OSM have been performed, and its relation to coronary heart disease (CHD) has not been studied. APPROACH AND RESULTS: Gene...
article 2019
document
Fuijkschot, W.W. (author), Morrison, M.C. (author), Zethof, I.P.A. (author), Krijnen, P.A.J. (author), Kleemann, R. (author), Niessen, H.W.M. (author), Smulders, Y.M. (author)
Background and Aims: Observational studies show a peak incidence in cardiovascular events during and early after clinical conditions associated with substantial systemic inflammation, such as pneumonia. The acuteness of this increased risk suggests rapid plaque destabilization and associated intraplaque inflammation. We evaluated whether...
article 2018
document
Woudstra, L. (author), Meinster, E. (author), van Haren, L. (author), Kay, A.M. (author), Kooman, M. (author), Belien, J.A.M. (author), Morrison, M.C. (author), van Rossum, A.C. (author), Helder, M.N. (author), Juffermans, J.M. (author), Niessen, H.W.M. (author), Krijnen, P.A.J. (author)
Background aims. After a myocardial infarction (MI) atherosclerosis is accelerated leading to destabilization of the atherosclerotic plaque. mesenchymal stromal cells are a promising therapeutic option for atherosclerosis. Previously, we demonstrated a novel stem cell delivery technique, with adipose stem cells coupled to microbubbles (i.e.,...
article 2018
document
Luque-Sierra, A. (author), Alvarez-Amor, L. (author), Kleemann, R. (author), Martín, F. (author), Varela, L.M. (author)
Scope: The present study investigates the effect of olive oils with different phenolic content in high-fat diets (HFDs) on hypertrophy and inflammation in adipose tissue and associated atherosclerosis, in the context of obesity. Methods and results: Ldlr−/−.Leiden mice were fed three different HFDs for 32 weeks and were compared with mice fed...
article 2018
document
Aldi, S. (author), Matic, L.P. (author), Hamm, G. (author), van Keulen, D. (author), Tempel, D. (author), Holmstrøm, K. (author), Szwajda, A. (author), Nielsen, B. (author), Emilsson, V. (author), Ait-Belkacem, R. (author), Lengquist, M. (author), Paulsson-Berne, G. (author), Eriksson, P. (author), Lindeman, J.H.N. (author), Gool, A.J. (author), Stauber, J. (author), Hedin, U. (author), Hurt-Camejo, E. (author)
Variants in the PLPP3 gene encoding for lipid phosphate phosphohydrolase 3 have been associated with susceptibility to atherosclerosis independently of classical risk factors. PLPP3 inactivates lysophosphatidic acid (LPA), a pro-inflammatory, pro-thrombotic product of phospholipase activity. Here we performed the first exploratory analysis of...
article 2018
document
Hoeke, G. (author), Wang, Y. (author), van Dam, A.D. (author), Mol, M. (author), Gart, E. (author), Klop, H.G. (author), van den Berg, S.M. (author), Pieterman, E.H. (author), Princen, H.M.G. (author), Groen, A.K. (author), Rensen, P.C.N. (author), Berbée, J.F.P. (author), Boon, M.R. (author)
Background and aims Activation of brown adipose tissue (BAT) reduces both hyperlipidemia and atherosclerosis by increasing the uptake of triglyceride-derived fatty acids by BAT, accompanied by formation and clearance of lipoprotein remnants. We tested the hypothesis that the hepatic uptake of lipoprotein remnants generated by BAT activation...
article 2017
document
Landlinger, C. (author), Pouwer, M.G. (author), Juno, C. (author), van der Hoorn, J.W.A. (author), Pieterman, E.J. (author), Jukema, J.W. (author), Staffler, G. (author), Princen, H.M.G. (author), Galabova, G. (author)
Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low density lipoprotein cholesterol (LDLc) and a higher...
article 2017
document
Mulder, P.C.A. (author)
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common cause of chronic liver disease, and its worldwide prevalence continues to increase in parallel of the obesity epidemic. NAFLD comprises a wide spectrum of liver damage ranging fat accumulation (steatosis) to steatosis with inflammation (non-alcoholic steatohepatitis,...
doctoral thesis 2017
document
Salic, K. (author), Morrison, M.C. (author), Verschuren, L. (author), Wielinga, P.Y. (author), Wu, L. (author), Kleemann, R. (author), Gjorstrup, P. (author), Kooistra, T. (author)
Background and aims Besides LDL-cholesterol, local vascular inflammation plays a key role in atherogenesis. Efficient therapies to treat the inflammatory component of the disease have not been established. The discovery of specialized inflammation-resolving mediators, such as resolvins may provide new opportunities for treatment. This study...
article 2016
Searched for: subject:"atherosclerosis"
(1 - 20 of 133)

Pages